Ecotest Flu ABC+RSV Rapid Antigen Pen
RSV, Influenza A+B & COVID-19 Nasal Test
The RSV, Influenza A/B & COVID-19 Antigen Nasal Test Kit is an in-vitro immunoassay that detects viral nucleocapsid proteins of SARS-CoV-2, Influenza A virus, Influenza B virus and viral antigens of respiratory syncytial virus (RSV) from a simple nasal swab. Ideal for medical practice or home testing, the user-friendly and easy-to-administer design can help in diagnosing a range of respiratory viruses, giving quick and accurate results.
Versatile test with flexible fulfilment
Ecotest RSV + ABC Tests feature a patented design and are convenient to store, stack or display, as well as easy to use and dispose of. Our tests are ideal for government, corporate or private applications, and are available for delivery in custom order quantities of 2, 5 and 20 packs, to suit your distribution needs.
Speak to salesConvenient 4-in-1 viral testing
Designed to be non-invasive and easy to self-administer, the Ecotest RSV + ABC Test Pen’s patented two-step design streamlines the process of testing for common seasonal viruses (SARS-CoV-2, Influenza A, Influenza B, and RSV). Test by swabbing your nose, then placing the pen into its buffer cap, and reading results in 15 minutes. No need for extra components, or mixing reagents: it’s as easy as that.
Biolink can help your business save money and time with our range of rapid antigen tests.
Two-step procedure
STEP 1. Remove the protector and insert the nasal collector into a nostril. Rotate the collector 5 times against the nasal wall. Repeat in other nostril.
STEP 2. Place the test device vertically into the tube with the extraction buffer. Ensure the top of the base aligns to the middle of the supporting line.
NOTE: Wait 15 minutes, then check your results. Do not read results after 30 minutes, as they will be invalid.
Results interpretation (COVID)
COVID Positive
COVID Negative
Invalid
Results interpretation (RSV)
RSV Positive
RSV Negative
Invalid
Results interpretation (Influenza A+B)
Influenza A
Positive
Influenza B
Positive
Influenza A+B
Positive
Influenza A+B Negative
Invalid
COVID, Influenza A+B & RSV test specifications
| Assay format | Lateral flow |
|---|---|
| Type | Pen |
| Testing time | 15 minutes to results; maximum 30 minutes |
| Antigen | Nucleocapsid protein (N) |
| Sample material | Nasopharyngeal swab |
| Reagents | TBC |
Clinical evaluation
| COVID sensitivity | 97.0% (91.6% ~99.0%) |
|---|---|
| COVID specificity | 99.3% (98.1% ~99.8%) |
| Influenza A sensitivity | 94.3% (86.2% ~97.8%) |
| Influenza A specificity | 98.8% (97.3% ~99.4%) |
| Influenza B sensitivity | 93.9% (80.4% ~98.3%) |
| Influenza B specificity | 99.0% (97.8% ~99.6%) |
| RSV sensitivity | 91.4% (77.6% ~97.0%) |
| RSV specificity | 98.8% (97.5% ~99.5%) |
About Biolink
Global Clientele
International supplier of rapid antigen tests to government and multi-industry clients
End-to-end
Access to global supply networks and technologies to support your brand
Rapid & Reliable
Rapid and reliable shipping and logistics to support your network and supply chain
Versatile
Experts in at-home and point-of-care rapid testing across Europe, Australia, and North America
Easy
Straightforward ordering and distribution processes, with 24-hour global support channels
Safe
We work with specialists in user-friendly rapid antigen pens and cassettes for various diseases
Get in touch
Drop us a line. We'll get back to you as soon as we can.
More details
Made for convenience
Our pens are designed to be used in scenarios that don't allow for the easy mixing of reagents or buffer solutions. This makes it ideal for use in locations like schools, workplaces, day-cares, or hospitals, where it may be hard or inconvenient to perform a cassette style test. Just as quick and accurate as other RATs; but an easier, more comfortable user experience.
Summary of use
The COVID-19 & Influenza A+B & RSV Antigen Nasal Test Kit is an in-vitro immunoassay intended for the qualitative detection of antigens in nasal swab specimens from patients with COVID-19, and/or RSV (within first 7 days of symptom onset), and/or Influenza A+B (within first 4 days of symptom onset). This test doesn't discriminate between SARS-coronavirus and SARS-CoV-2 (COVID-19).
Precautions for use
The test is intended for point-of-care use; and not intended for home testing (or self-testing). It obtains a preliminary result only, to aid diagnosis of COVID-19, Influenza A+B, and RSV. Please note that negative results do not preclude viral infections—test results should not be the sole basis for treatment or other management decisions.